Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sales of 4 Japan Drug Majors Dip 3.7% on Stronger Yen, Price Cuts; Global Brands Solid
May 12, 2017
-
BUSINESS Meiji Seika Pharma Forms Generic Subsidiary
May 10, 2017
-
REGULATORY LDP Confab Sees Japan Execs’ Chorus for Drug Price Maintenance during Patent Term
May 10, 2017
-
BUSINESS Sales Rep Survey - 1: Foreign Drug Makers’ Downsizing Drive Unabated
May 9, 2017
-
BUSINESS 60% of Drug Makers Increase New Grad Hires in FY2017, Otsuka Tops List: Jiho Tally
May 9, 2017
-
REGULATORY “Specified Clinical Research” Data with High Integrity Could Be Used for Drug Review: MHLW Councilor
May 8, 2017
-
REGULATORY MHLW Study Group Drafts “Items to Consider” to Promote Development of Nucleic Acid Drugs
May 2, 2017
-
REGULATORY MHLW Poised to Create Standards for Cancer Treatment in the Elderly
May 1, 2017
-
REGULATORY 2017 Economic and Fiscal Policy Guidelines Likely to Be Tinged with MOF Color
April 28, 2017
-
BUSINESS Astellas Sales Dip 4.4% on Forex Moves, Japan Biz Dented by Price Cuts
April 28, 2017
-
REGULATORY JMA’s Nakagawa Says MHLW Should Fuel Generic Industry Realignment: Chuikyo
April 27, 2017
-
REGULATORY Me-Too Drugs in Jeopardy? CEFP Working Group Pushes Rigid Drug Selection for Innovation Premium
April 26, 2017
-
REGULATORY LDP Health Panel to Compile Resolution on Drug Pricing
April 25, 2017
-
BUSINESS Mundipharma Japan Chief Voices Eagerness on Rare Cancer Therapies
April 25, 2017
-
REGULATORY Sakigake Fast-Track Designation Given to Aducanumab, 4 Other Products
April 24, 2017
-
REGULATORY MOF Calls for Scrapping Price Maintenance Premium
April 21, 2017
-
ORGANIZATION Innovation Premium Top Priority for 3 Trade Groups; EFPIA Ideally Wants Its Expansion
April 20, 2017
-
BUSINESS Xarelto Issue Morally Questionable, but Does Not Constitute Misleading Ads Banned under Law: MHLW Officials
April 20, 2017
-
COMMENTARY Will Government Take the Lead in Pricing Debate towards 2017 Fiscal Blueprint?
April 19, 2017
-
BUSINESS Boehringer Japan Logs 14 Consecutive Years of Growth in Ethical Drug Sales
April 18, 2017
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…